Dr. Hertzel Gerstein

Division of Endocrinology and Metabolism

Hertzel C. Gerstein

M.D., MSc, FRCPC

Professor, Department of Medicine

Associate Member, Department of Clinical Epidemiology & Biostatistics

Director, Division of Endocrinology & Metabolism

Director, Diabetes Care and Research Program, McMaster University, Hamilton Health Sciences

Deputy Director, Population Health Research Instutite

Population Health Institute Chair in Diabetes Research

 

Education and Professional Standing

Dr. Hertzel C. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He has received several honors including McMaster University’s Jack Hirsh Award (2016) and the Canadian Diabetes Association’s Lifetime Achievement Award (2012).

Academic Interests

Dr. Gerstein has led the application of large simple outcome trials to people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. He currently leads clinical research focused on: a) the prevention and therapy of diabetes and its many consequences; b) diabetes remission; and c) the link between dysglycemia and vasculopenia, cardiovascular disease, cognitive impairment and other disorders. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Key trials in which he has played or continues to play a major leadership role include HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, ORIGINALE, TIDE, ELIXA, ACE, and REWIND. In addition to his research, he was the founding director of Diabetes Hamilton – a novel public program that facilitated the ability of people with diabetes to manage their disease; and produced a music video focused on destigmatizing diabetes for affected people (https://www.youtube.com/watch?v=Qmh4qGLd2Tk).

Selected Publications

Dr. Gerstein has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues and co-edited the textbook Evidence-Based Diabetes Care. He is an Associate Editor for ACP Journal Club, and is on the editorial board of the Journal of Diabetes. He was the founding chair of the evidence-based committee for the CDA Evidence-based Clinical Practice Guidelines for the Management of Diabetes in Canada and developed their evidence-based approach. Selected publications are noted below.

  1. Gerstein HC, Paré G, McQueen MJ, Haenel H, Lee SF, Pogue J, Maggioni AP, Yusuf S, Hess S, ORIGIN Trial Investigators. Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation 2015;132:2297-304.
  2. Gerstein HC. Diabetes: Dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11:508-510. 
  3. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, Booth GL, for the ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014; 384(9958):1936-41.
  4. Gerstein HC, Werstuck G. Dysglycemia, vasculopenia and the chronic consequences of diabetes. Lancet Diabetes and Endocrinology 2013; 1:71-78.
  5. Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic retinopathy, its progression and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013; 36(5):1266-71.
  6. Gerstein HC for the ORIGIN Trial Investigators. Basal insulin and cardiovascular and other health outcomes in dysglycemia. N Engl J Med 2012; 367:319-328.
  7. Gerstein HC for the ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med; 2011:364(9):818-28.
  8. Gerstein HC, Islam S, Anand S, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia. 2010: 53(12):2509-17.
  9. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298.
  10. Gerstein HC for the DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
  11. Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia, cardiovascular and renal risk in diabetic and nondiabetic participants in the HOPE study: A prospective epidemiologic analysis. Diabetologia 2005; 49:1749-1755.
  12. Gerstein HC, Mann JFE, Pogue J, et al. The albumin/creatinine ratio is a continuous risk factor for future cardiovascular events in diabetic and non-diabetic individuals. JAMA 2001;286:421-426.
  13. Gerstein HC for the HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE and MICRO-HOPE Study. Lancet 2000;355:253-259.
  14. Gerstein HC, Haynes RB eds. Evidence-Based Diabetes Care .BC. Decker Inc. Hamilton 2001 (Textbook).
  15. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2):233-240.
  16. Gerstein HC, Yusuf S. Dysglycemia and the risk of cardiovascular disease. Lancet 1996; 347:949-950.